Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA expression profiling A549 lung cancer cells following PPARGC1A suppression

ABSTRACT: mRNA expression profiling A549 lung cancer cells following PPARGC1A suppression

PROVIDER: PRJNA659234 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12514551_1.fastq.gz	Fastqsanger.gz
	SRR12514551_2.fastq.gz	Fastqsanger.gz
	SRR12514552_1.fastq.gz	Fastqsanger.gz
	SRR12514552_2.fastq.gz	Fastqsanger.gz
	SRR12514553_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

mRNA expression profiling A549 lung cancer cells following PPARGC1A suppression

Project description:PPARGC1A oppositely regulates cancer metastasis in melanoma, breast, and pancreatic cancer; however, little is known about its impact on lung cancer metastasis. We generated gene-expression profile of control and PPARGC1A suppressed A549 cells, a lung adenocarcinoma cell line that expresses moderate levels of PPARGC1A to investigate the role of this gene in lung cancer metastasis.

2021-08-16 | GSE156833 | GEO

RNA-seq of human oesophageal adenocarcinoma OE19 cell line following PPARGC1A knock-down and 24 hour lapatinib treatment

Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.

2022-09-26 | E-MTAB-10317 | biostudies-arrayexpress

Effect of Ppargc1a overexpression in mouse heart

Project description:Ppargc1a overexpression in heart tissue measured using RNA sequencing

2017-09-08 | GSE77795 | GEO

Lung Adenocarcinoma (A549) Immunopeptidomics

Project description:Alterations in cellular antigen processing and presenting machinery has gained increased interest as a hallmark of cancer-related inflammation. Growing evidence suggest that proteasome composition and immunoproteasome expression can influence antigen processing. By performing immunopeptidomics on A549 lung adenocarcinoma cell line following depletion of proteasome regulator PSME4 we identified alterations in the antigenic landscape resulting from changes in proteasome processing.

2023-03-30 | PXD037365 | Pride

Lung Adenocarcinoma (A549) Immunopeptidomics

2023-03-30 | PXD028364 | Pride

Impact of knocking out Ppargc1a in intestinal stem cells on mucosal homeostasis

Project description:We report the application of single cell RNAseq assay in examining the effect of Ppargc1a gene expression in intestinal stem cells on mucosal homeostasis. Lgr5EGFPcreERT2 mice were crossed with Ppargc1a F/+ or F/F to selectively target gene expression in Lgr5 expressing intestinal stem cells. Mice were fed with control diet AIN76A from weaning for 3 months, and deletion of Ppargc1a gene was conducted via Tamoxifen injection. Mice were sacrificed 3 days post tamoxifen injection.

2023-04-12 | GSE188339 | GEO

GLIDR-mediated Regulation of Tumor Malignancy and Cisplatin Resistance in Non-Small Cell Lung Cancer via the miR-342-5p/PPARGC1A Axis

Project description:LncRNAs play a crucial role in regulating the progression of NSCLC, making them potential targets for cancer diagnosis and treatment. Therefore, identifying new lncRNAs as therapeutic target and comprehending their underlying regulatory mechanisms are crucial for treating NSCLC. In this study, we found that glioblastoma down-regulated RNA (GLIDR) was increased in non-response NSCLC patients with the primary treatment, and GLIDR was also highly expressed in NSCLC patients. We used bioinformatic analysis and luciferase assays to identify that microRNA-342-5p (miR-342-5p) directly targets GLIDR. MiR-342-5p overexpression inhibits NSCLC cell proliferation, migration, and invasion, whereas miR-342-5p inhibition promotes NSCLC malignancy, which can be rescued by suppressing GLIDR. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PPARGC1A) was identified as a downstream target of miR-342-5p. PPARGC1A inhibition significantly suppresses NSCLC malignancy, whereas overexpression promotes it. The results also revealed that GLIDR overexpression reduced PPARGC1A inhibition by miR-342-5p, and increased PPARGC1A expression reversed the inhibition of NSCLC malignancies caused by decreased GLIDR. To the best of our knowledge, we are the first to discover that GLIDR promotes NSCLC progression by sponging miR-342-5p to regulate PPARGC1A expression, presenting that GLIDR act as a potential therapeutic target in NSCLC.

2023-11-16 | GSE243455 | GEO

mRNA expression profile of A549 cells and MSR-A549 cells with or without JQ1 treatment

Project description:To establish effective multitargeted KRAS pathway therapy, we analyzed mediators of acquired resistance to chronic momelotinib and MEK inhibitor exposure in A549 cells. Since inhibitor resistance was completely reversible after drug withdrawal for several passages, suggesting epigenetic reprogramming, we investigated whole mRNA expression profiles in A549, momelotinib and selumetinib resistant (MSR)-A549 cells and MSR-A549 cells following drug withdrawal for 10 days. In parallel, we also examined mRNA expression profiles of MSR-A549 cells treated with the BET inhibitor JQ1, to identify specific targets regulated by H3K27 acetylation.

2019-03-28 | GSE96779 | GEO

miRNA expression of lung cancer cells A549 and cisplatin (DDP) resistant lung cancer cells A549/DDP

Project description:To investigate the difference of miRNA expression between lung cancer cell A549 and its DDP-resistant cell strain A549/DDP, we have employed miRNA microarray expression to discover the difference expression of miRNAs of A549 cells and A549/DDP. We conducted RT-qPCR to examine the expression levels of top differential expressed miRNAs, namely, miR-197-5p, miR-4443, miR-642a-3p, miR-27b-3p and miR-100-5p, confirming low variability between two methods. The A549/DDP was established from A549 in our laboratory, by exposing A549 to gradually increasing DDP concentrations, until the final concentration at 1Î¼g/ml. To avoid the influence of drug to the A549/DDP cells, they were cultured in a drug-free medium for at least two weeks before gene expression analysis. miRNA expression of A549 and A549/DDP was then analzyed.

2016-08-16 | E-GEOD-85603 | biostudies-arrayexpress

RNA-seq assessment of quadriceps muscle and brown adipose tissue in PPARGC1A uORF-TAA mice

Project description:We report a mutant mouse in which the uORF encoded by the PPARGC1A gene is disrupted via mutation of its start codon (uORF-TAA mutation). RNA-seq was used to assess differential gene expression in uORF-TAA versus wild-type mice in two metabolically important tissues that express PPARGC1A: skeletal mucle and brown adipose tissue.

2019-06-01 | GSE129687 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data